GlucoModicum’s non-invasive glucose monitoring technology performs 13x better than previous needle-free approaches

GlucoModicum's Not- -invasive glucose monitoring technology Performance 13x better than previous needle- -free approaches

- Data published in Scientific Reports, part of the Nature Portfolio Journals, paves the way for groundbreaking wearable solutions for monitoring diabetes -

Helsinki, Finland, April 20, 2021 - GlucoModicum, an innovator in needle-free health and biomarker monitoring solutions, announces that research data on its proprietary magnetohydrodynamics ("MHD") technology to measure glucose levels in the skin without needles has been published in Scientific Reports, Part 1 of the Nature Research portfolio, the world's leading multidisciplinary scientific journals. These peer-reviewed results show that GlucoModicum's novel approach to dermal interstitial fluid collection was 13 times faster and more effective than its predecessor, reverse iontophoresis.

Blood glucose testing is critical to the diagnosis and treatment of diabetes. However, there are currently no needle-free solutions for measuring blood glucose on the market. Invasive technologies currently available can be painful, time consuming, and cause extreme glucose levels to go unnoticed as people don't want to stick needles into their bodies to monitor their health. There is therefore a strong need for the development of a non-invasive glucose sensor and continuous glucose monitoring devices.

However, high quality, non-invasive sampling of interstitial fluid was the missing piece of the puzzle to enable accurate needle-free glucose monitoring through portable devices. GlucoModicum believes it has high performance technology to overcome this. With this data, the company is expanding its portable glucose monitoring solution based on its MHD technology.

GlucoModicum combines its novel platform technology with the development of highly sensitive biosensors and advanced algorithms, paving the way for groundbreaking ways to monitor diabetes, both as a portable device and remotely for healthcare professionals. This approach to measuring glucose levels is non-invasive and offers a skin-friendly solution that enables needle-free and continuous glucose monitoring and provides quick and accurate results. GlucoModicum's MHD technology was discovered in 2016 as part of a scientific research project at the University of Helsinki.

Jokke Mäki, C.raised E.xecutive Öfficer of GlucoModicum, comments: “These results demonstrate an important validation point for GlucoModicum's unique MHD technology and confirm our belief that we can offer patients a much-needed, needle-free alternative to glucose monitoring. We are focused on translating this exciting science into wearable technology that can ultimately reduce the patient burden associated with diabetes. "

This data follows GlucoModicum's successful patent approval with broad market coverage for the core technology platform. In subsequent publications, GlucoModicum will publish more meaningful data on the applications of its technology.

In 2019, the Finnish Health Authority (HUS) approved the industrial prototype of GlucoModicum for clinical trials in type 2 diabetics. In addition, the Finnish Agency for Drugs and Medical Devices (FIMEA2) has reviewed GlucoModicum's clinical study plans. In compliance with these protocols, GlucoModicum has already carried out a successful clinical study with 50 type 2 diabetics. In the ongoing clinical studies, GlucoModicum can enroll up to 240 patients.

GlucoModicum miniaturized and productive its technology to develop a commercial grade medical device. The "Talisman" shown above is the product version currently under development.

DR. Alejandro GarcIa, C.raised T.Echnology Öfficer at GlucoModicum, said: “These results confirm the validity of our technology for monitoring non-invasive biomarkers. The study represents an important advancement for people with type 2 diabetes and demonstrates the strength of the GlucoModicum platform to enable monitoring of glucose and ultimately additional valuable analytes. "

- END -

About GlucoModicum

GlucoModicum is an innovator in needle-free solutions for health and biomarker monitoring. Founded in 2018 as a spinout from the University of Helsinki, GlucoModicum combines an experienced, multidisciplinary in-house team with world-class product and manufacturing partners to provide breakthrough solutions for personal biomarker monitoring. GlucoModicum's solutions are based on the new platform technology for non-invasive sampling and use the latest miniaturized biosensors and algorithms. They can improve the health and quality of life of hundreds of millions of people around the world. GlucoModicum has not only received private funding from investors with extensive knowledge of the MedTech domain, but also significant public funding from Business Finland, the Finnish government's funding agency for high-impact innovations. Further information is available at: www.glucomodicum.com

over D.diabetes

Diabetes affects 463 million people worldwide and has an annual healthcare cost of $ 800 billion, a major public health and economic concern. Additionally, 374 million people worldwide have impaired glucose tolerance (IGT) - a high risk status for diabetes. Portable devices for continuous self-monitoring of glucose can play a crucial role in both the prevention and treatment of diabetes. However, the current lack of truly non-invasive solutions prevents these devices from becoming widespread.

For more information, please contact:

GlucoModicum

Jokke Mäki
managing Director

Email: info@glucomodicum.com

The design strategic communication

Amber Fennell, Carina Jurs and Maya Bennison

Email: glucomodicum@consilium-comms.com

1 https://www.nature.com/articles/s41598-021-86931-7 Sampling fluid through the skin using magnetohydrodynamics for non-invasive glucose monitoring

2 The Finnish Medicines Agency FIMEA is the national competent authority for the regulation of medicines, medical devices, blood and tissue products and biobanks and assists in the development of these sectors in Finland.

continue reading http://dailytechnonewsllc.com/glucomodicums-non-invasive-glucose-monitoring-technology-performs-13x-better-than-previous-needle-free-approaches/?feed_id=6128&_unique_id=61d0fd48d1951